Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Summary

This research study is studying a drug as a possible treatment for High Grade Meningioma.

Timeline

Start

2020-06-01

Primary completion

2023-06-01

Completion

2025-06-01

Outcome

Missed primary endpoint

paper Sintilimab failed to improve PFS-6 in both grade 1 and grade 2/3 recurrent/progressive meningiomas in this single-arm, single-center, and small-sample trial. PMID 41358608 ↗

Publications

• Wang Y, Wang C, Yin S, Yu C, Li X, Kang X, Yang S, Xie W, Lin Y, Wu Z, Li W, Chen F. Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma. CNS Neurosci Ther. 2025 Dec;31(12):e70659. doi: 10.1111/cns.70659.

Drugs

Indications